



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/030,985
	Filing Date	2/26/98
	First Named Inventor	LOUIS D. FALO
	Group Art Unit	1644
	Examiner Name	F. VANDER VEGT
Total Number of Pages in This Submission	Attorney Docket Number	214001-00648

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input checked="" type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

APR 19 2000

TECH CENTER 1600/2900

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Diane R. Meyers, Esquire Eckert Seamans Cherin & Mellott, LLC
Signature	
Date	4/13/00

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 4/13/00			
Typed or printed name	Diane R. Meyers, Esquire		
Signature		Date	4/13/00

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

C

AF/6AM-1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of:

LOUIS D. FALO, et al.

Serial No. 09/030,985

Filed February 26, 1998

Entitled:

INDUCTION OF TUMOR AND VIRAL
IMMUNITY USING ANTIGEN
PRESENTING CELLS CO-CULTURE
PRODUCTS AND FUSION PRODUCTS

Examiner F. VanderVegt

Group Art Unit 1644

Attorney Docket No. 214001-00648

#14/C
[Signature]

APR 19 2000
TECH CENTER 1600/2900

AMENDMENT

April 13, 2000

Assistant Commissioner for Patents
BOX AF
Washington, DC 20231

Sir:

This is in response to a telephone interview with the Examiner on April 11, 2000, in connection with the above captioned case. The following amendment is believed to put the case in condition for allowance.

Please amend the above-identified application as follows:

In The Claims:

13. (Once Amended) A [formulation] composition comprising the products of co-culture[s] of a plurality of first cells and a plurality of second cells; wherein said first cells are antigen presenting cells selected from the group consisting of macrophages, B-cells and dendritic cells, and said second cells are selected from the group consisting of tumor cells and virally infected cells, wherein said first cells present an array of antigens from said second cells.

In Claim 14, line 1, delete "formulation" and insert -- composition --.
In Claim 15, line 1, delete "formulation" and insert -- composition --.
In Claim 16, line 1, delete "formulation" and insert -- composition --.
In Claim 17, line 1, delete "formulation" and insert -- composition --.
In Claim 18, line 1, delete "formulation" and insert -- composition --.

OK TO ENTER
5/17/2000
[Signature]

C.

24